Drug intelligence / Profile preview

131I-labeled antitumor antibody

Development stage: Unknown
Lead developer: Duke University Medical Center
Modality: Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

The "131I-labeled antitumor antibody" is a type of radiopharmaceutical used for cancer treatment. It combines a monoclonal antibody with iodine-131 (131I), a radioactive isotope, to target and deliver radiation directly to tumor cells. This approach is designed to minimize damage to healthy tissues while effectively killing cancer cells.

Other names: Radiolabeled monoclonal antibody131I-labeled antibody

Targets

CD274 (Programmed cell death protein 1 ligand 1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)αVβ3 (Integrin αVβ3)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on 131I-labeled antitumor antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 131I-labeled antitumor antibody.

Explore the full profile